Moderna, Inc. (NASDAQ:MRNA) CFO James M. Mock Sells 715 Shares

Moderna, Inc. (NASDAQ:MRNA) CFO James M. Mock sold 715 shares of the firm’s stock in a transaction that occurred on Monday, October 7th. The stock was sold at an average price of $60.12, for a total transaction of $42,985.80. Following the sale, the chief financial officer now owns 9,505 shares in the company, valued at approximately $571,440.60. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Moderna Stock Performance

Moderna stock traded down $0.32 during midday trading on Tuesday, reaching $58.40. 3,160,873 shares of the stock traded hands, compared to its average volume of 4,335,362. The firm has a fifty day moving average price of $77.18 and a two-hundred day moving average price of $107.72. Moderna, Inc. has a fifty-two week low of $57.75 and a fifty-two week high of $170.47. The firm has a market cap of $22.38 billion, a price-to-earnings ratio of -3.75 and a beta of 1.66. The company has a current ratio of 4.09, a quick ratio of 3.92 and a debt-to-equity ratio of 0.05.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings data on Thursday, August 1st. The company reported ($3.33) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($3.47) by $0.14. Moderna had a negative return on equity of 21.35% and a negative net margin of 116.18%. The business had revenue of $241.00 million during the quarter, compared to analyst estimates of $128.41 million. During the same period in the prior year, the company posted ($3.62) EPS. The business’s revenue for the quarter was down 29.9% compared to the same quarter last year. On average, equities research analysts forecast that Moderna, Inc. will post -9.86 earnings per share for the current year.

Wall Street Analyst Weigh In

MRNA has been the topic of a number of recent analyst reports. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $75.00 price target on shares of Moderna in a research note on Thursday, September 19th. Needham & Company LLC reaffirmed a “hold” rating on shares of Moderna in a research note on Friday, September 13th. TD Cowen cut their price target on shares of Moderna from $70.00 to $60.00 and set a “hold” rating on the stock in a research note on Friday, September 13th. Oppenheimer downgraded shares of Moderna from an “outperform” rating to a “market perform” rating in a research note on Friday, September 13th. Finally, Piper Sandler reduced their target price on shares of Moderna from $157.00 to $115.00 and set an “overweight” rating on the stock in a report on Friday, September 13th. Two analysts have rated the stock with a sell rating, thirteen have given a hold rating and four have assigned a buy rating to the company. According to MarketBeat, Moderna currently has an average rating of “Hold” and an average price target of $100.44.

Institutional Investors Weigh In On Moderna

A number of hedge funds and other institutional investors have recently modified their holdings of MRNA. Vanguard Group Inc. boosted its stake in Moderna by 15.1% in the 1st quarter. Vanguard Group Inc. now owns 39,036,872 shares of the company’s stock worth $4,159,769,000 after purchasing an additional 5,129,800 shares during the period. Wellington Management Group LLP increased its holdings in shares of Moderna by 28.8% in the 4th quarter. Wellington Management Group LLP now owns 7,225,579 shares of the company’s stock valued at $718,584,000 after purchasing an additional 1,614,460 shares during the period. Capital World Investors boosted its holdings in shares of Moderna by 0.5% during the first quarter. Capital World Investors now owns 3,648,117 shares of the company’s stock worth $388,743,000 after purchasing an additional 18,728 shares during the period. Mawer Investment Management Ltd. grew its position in Moderna by 6.7% during the first quarter. Mawer Investment Management Ltd. now owns 1,916,570 shares of the company’s stock valued at $204,230,000 after purchasing an additional 120,621 shares in the last quarter. Finally, Bellevue Group AG increased its stake in Moderna by 27.6% in the 4th quarter. Bellevue Group AG now owns 1,908,420 shares of the company’s stock valued at $189,792,000 after buying an additional 413,095 shares during the period. 75.33% of the stock is currently owned by institutional investors.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.